In addition to inhibiting PD-L1/PD1 axis, glycolysis inhibitors can also be used to directly inhibit tumor cell metabolism, however, the metabolic similarities between tumor cells and immune cells may lead to direct inhibition of tumor cell metabolism, which could impact the efficacy of immunotherapy. Here, CD274 is linked to neoplasm.